Jing Medicine Technology Shanghai

Shanghai Jingxin Pharmaceutical Technology (Jing Medicine Technology Shanghai) is the primary R&D subsidiary of Zhejiang Jingxin Pharmaceutical. Located in Shanghai's Zhangjiang Hi-Tech Park, the company focuses on the discovery and development of innovative small molecule therapeutics across several therapeutic areas, including the central nervous system (CNS), digestive system, and oncology. The company manages a robust pipeline featuring late-stage candidates such as the GABA-A receptor modulator EVT201 for insomnia and the P-CAB inhibitor JX-02 for gastric disorders. As a high-tech R&D hub, it facilitates international collaborations and technology licensing to drive the parent company's transition from a generic-focused manufacturer to an innovation-led pharmaceutical enterprise. The center integrates advanced medicinal chemistry and pharmacology to develop first-in-class and best-in-class treatments for the Chinese and global markets.